Oakrum Pharma has entered into an agreement with Aucta Pharmaceuticals to develop and manufacture four prescription generic pharmaceutical products that are intended to be commercialized in the U.S. under the Oakrum label. It is anticipated that the products will serve the retail market and will include oral solutions and topicals. The total addressable market for the products in the U.S. exceeded $300 million in the aggregate for the 12-month period ending December 31, 2018 according to available data from IQVIA.
"We are excited to partner with Aucta on our first external product development collaboration. Aucta provides unique product development capabilities and scientific expertise that should grant Oakrum access to difficult-to-formulate products, and these products will contribute to our objective of bringing more affordable specialty and rare disease prescription products to market,” Marco Polizzi, CEO of Oakrum, said. “These products are part of our growing pipeline of unique and high-quality affordable medicines."
"We selected Oakrum to be our exclusive U.S. marketer for these products because of the commercialization expertise the Oakrum team will bring to this collaboration," Shoufeng Li, CEO of Aucta, said.